A new schedule for Etoposide, Epidoxorubicin and Cisplatin with Granulocyte Colony Stimulating Factor for advanced gastric cancer: A feasibility study

Paolo Pronzato, Antonella Vigani, Floriana Pensa, Floriana Botto, Ermanno Ghio, Elisabetta Neri, Alessandra Tognoni, Franco Vaira

Research output: Contribution to journalArticlepeer-review

Abstract

A new polychemotherapy regimen has been developed for gastric cancer. Etoposide at the dose of 120 mg/m2 for three days, Epidoxorubicin at the dose of 30 mg/m2 on day 1 and Cisplatin at the dose of 40 mg/m2 on day 2 were administered to 26 advanced gastric patients every two weeks with the support of Granulocyte Colony Stimulating Factor from day 8 to day 12 of each cycle. The treatment was feasible with most cases (21/25) having received at least four cycles with a dose intensity > 85%, without lifethreatening side effects. Toxicity was lower than that observed in the classical combination of Etopside- Anthracycline-Cisplatin.

Original languageEnglish
Pages (from-to)3873-3876
Number of pages4
JournalAnticancer Research
Volume17
Issue number5 B
Publication statusPublished - Sep 1997

Keywords

  • Gastric cancer dose intensity
  • Granulocyte colony stimulating factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A new schedule for Etoposide, Epidoxorubicin and Cisplatin with Granulocyte Colony Stimulating Factor for advanced gastric cancer: A feasibility study'. Together they form a unique fingerprint.

Cite this